A Randomized Trial of Dual-Agent Fluorescence-Guided Surgery for Resection of Colorectal Liver Metastases

The trial enrolled adult patients diagnosed with colorectal liver metastases. Both male and female subjects were eligible, and the age distribution corresponded to the study’s predefined categories coded as 3 and 4. The sponsor did not provide the total number of participants. Participants were required to be in generally stable health aside from the target condition, and were selected from the patient population meeting the disease-specific criteria. No additional lifestyle restrictions or specific inclusion/exclusion criteria were detailed in the available information.

The study assesses the safety and efficacy of dual-agent fluorescence‑guided surgery for colorectal liver metastases in a clinical trial scheduled to recruit participants from May 2026 to June 2027. Eligible individuals attend an initial screening visit to confirm inclusion criteria, after which the surgical intervention is performed. Participants return for scheduled follow‑up assessments to monitor postoperative outcomes and imaging findings, concluding with an end‑of‑study visit that captures final safety and efficacy endpoints. Participant involvement spans from the screening appointment through the final assessment, with the total trial duration encompassing the defined recruitment period. Early termination of a participant’s involvement may occur in the event of significant adverse events, withdrawal of consent, or failure to adhere to protocol requirements.